Ke Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ke Cao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Adeline S. L. Ng
Department of Neurology, National Neuroscience Institute, Singapore, Singapore
1 shared publication- Edimansyah Abdin
Institute of Mental Health
1 shared publication Hui Jin Chiew
Department of Neurology, National Neuroscience Institute, Singapore, Singapore
1 shared publicationJinesh Mukesh Shah
Department of Neurology, Singapore General Hospital, Singapore, Singapore
1 shared publication- Jingwei Sim
Department of Neurology National Neuroscience Institute (Tan Tock Seng Hospital Campus) Singapore Singapore
1 shared publication Kok Pin Ng
Department of Neurology, National Neuroscience Institute, Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55 (10) , 516
Exploring changes in recognition and stigmatisation towards individuals with schizophrenia in Singapore
Introduction: Schizophrenia is a debilitating illness that causes long-term impairment in individuals and imposes an economic burden on society. Early recognition is essential for successful treatment outcomes. Mental health literacy—including recognition of and stigma towards mental illnesses—is crucial for guiding policy and informing targeted interventions. This study examined changes in schizophrenia recognition and stigma in Singapore over an 8-year period (2015–2023), as well as current trends in their sociodemographic correlates. Methods: The study used data from 2 nationwide cross-sectional studies on mental health literacy using a vignette approach. Singapore residents aged 18–65 years were recruited via disproportionate stratified sampling. Respondents were presented with a vignette of a person with schizophrenia, and recognition was assessed using an open-ended question. Stigmatising attitudes were assessed using the Personal Stigma Scale and the Social Distance Scale. Results: Correct recognition of schizophrenia increased from 11.5% to 15.1%, though the difference was not statistically significant. A lower “weak-not-sick” stigma score in the 2023 survey persisted after adjusting for sociodemographic differences between survey cohorts. Younger age and social contact with individuals with schizophrenia were associated with better recognition and less stigma. Individuals of Malay and Indian ethnicities attributed schizophrenia to a personal weakness but showed less social distancing. Conclusion: The lack of significant improvement in recognition may reflect the continued need for schizophrenia-specific public education. The lower personal stigma score observed in the 2023 survey may also reflect broader changes in mental health awareness. Future initiatives should focus on culturally tailored anti-stigma interventions for schizophrenia that are accessible to older individuals and leverage social contact.
- 6 October 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55 (10) , 516
Open AccessExploring changes in recognition and stigmatisation towards individuals with schizophrenia in Singapore
Introduction: Schizophrenia is a debilitating illness that causes long-term impairment in individuals and imposes an economic burden on society. Early recognition is essential for successful treatment outcomes. Mental health literacy—including recognition of and stigma towards mental illnesses—is crucial for guiding policy and informing targeted interventions. This study examined changes in schizophrenia recognition and stigma in Singapore over an 8-year period (2015–2023), as well as current trends in their sociodemographic correlates. Methods: The study used data from 2 nationwide cross-sectional studies on mental health literacy using a vignette approach. Singapore residents aged 18–65 years were recruited via disproportionate stratified sampling. Respondents were presented with a vignette of a person with schizophrenia, and recognition was assessed using an open-ended question. Stigmatising attitudes were assessed using the Personal Stigma Scale and the Social Distance Scale. Results: Correct recognition of schizophrenia increased from 11.5% to 15.1%, though the difference was not statistically significant. A lower “weak-not-sick” stigma score in the 2023 survey persisted after adjusting for sociodemographic differences between survey cohorts. Younger age and social contact with individuals with schizophrenia were associated with better recognition and less stigma. Individuals of Malay and Indian ethnicities attributed schizophrenia to a personal weakness but showed less social distancing. Conclusion: The lack of significant improvement in recognition may reflect the continued need for schizophrenia-specific public education. The lower personal stigma score observed in the 2023 survey may also reflect broader changes in mental health awareness. Future initiatives should focus on culturally tailored anti-stigma interventions for schizophrenia that are accessible to older individuals and leverage social contact.
- 11 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 198
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration
Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.
- 11 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 198
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration
Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.